Publications
Detailed Information
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke
Cited 641 time in
Web of Science
Cited 820 time in Scopus
- Authors
- Issue Date
- 2008-08-30
- Publisher
- Massachusetts Medical Society
- Citation
- N Engl J Med. 2008;359(12):1238-1251
- Keywords
- Aged ; Angiotensin-Converting Enzyme Inhibitors/therapeutic use ; Aspirin/*administration & dosage/adverse effects ; Benzimidazoles/therapeutic use ; Benzoates/therapeutic use ; Brain Ischemia/epidemiology/prevention & control ; Delayed-Action Preparations ; Dipyridamole/adverse effects/*therapeutic use ; Double-Blind Method ; Drug Therapy, Combination ; Factor Analysis, Statistical ; Female ; Hemorrhage/chemically induced ; Humans ; Kaplan-Meiers Estimate ; Male ; Middle Aged ; Myocardial Infarction/epidemiology ; Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*therapeutic use ; Proportional Hazards Models ; Recurrence/prevention & control ; Risk ; Stroke/*drug therapy/epidemiology/prevention & control ; Ticlopidine/adverse effects/*analogs & derivatives/therapeutic use ; Vascular Diseases/mortality
- Abstract
- BACKGROUND: Recurrent stroke is a frequent, disabling event after ischemic stroke. This study compared the efficacy and safety of two antiplatelet regimens--aspirin plus extended-release dipyridamole (ASA-ERDP) versus clopidogrel. METHODS: In this double-blind, 2-by-2 factorial trial, we randomly assigned patients to receive 25 mg of aspirin plus 200 mg of extended-release dipyridamole twice daily or to receive 75 mg of clopidogrel daily. The primary outcome was first recurrence of stroke. The secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes. Sequential statistical testing of noninferiority (margin of 1.075), followed by superiority testing, was planned. RESULTS: A total of 20,332 patients were followed for a mean of 2.5 years. Recurrent stroke occurred in 916 patients (9.0%) receiving ASA-ERDP and in 898 patients (8.8%) receiving clopidogrel (hazard ratio, 1.01; 95% confidence interval [CI], 0.92 to 1.11). The secondary outcome occurred in 1333 patients (13.1%) in each group (hazard ratio for ASA-ERDP, 0.99; 95% CI, 0.92 to 1.07). There were more major hemorrhagic events among ASA-ERDP recipients (419 [4.1%]) than among clopidogrel recipients (365 [3.6%]) (hazard ratio, 1.15; 95% CI, 1.00 to 1.32), including intracranial hemorrhage (hazard ratio, 1.42; 95% CI, 1.11 to 1.83). The net risk of recurrent stroke or major hemorrhagic event was similar in the two groups (1194 ASA-ERDP recipients [11.7%], vs. 1156 clopidogrel recipients [11.4%]; hazard ratio, 1.03; 95% CI, 0.95 to 1.11). CONCLUSIONS: The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel. There is no evidence that either of the two treatments was superior to the other in the prevention of recurrent stroke. (ClinicalTrials.gov number, NCT00153062.)
- ISSN
- 1533-4406 (Electronic)
- Language
- English
- URI
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18753638
http://content.nejm.org/cgi/reprint/359/12/1238.pdf
https://hdl.handle.net/10371/68329
- Files in This Item:
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.